[go: up one dir, main page]

NO20081327L - Kinoliner og terapeutisk anvendelse derav - Google Patents

Kinoliner og terapeutisk anvendelse derav

Info

Publication number
NO20081327L
NO20081327L NO20081327A NO20081327A NO20081327L NO 20081327 L NO20081327 L NO 20081327L NO 20081327 A NO20081327 A NO 20081327A NO 20081327 A NO20081327 A NO 20081327A NO 20081327 L NO20081327 L NO 20081327L
Authority
NO
Norway
Prior art keywords
alkyl
cycloalkyl
group
heteroaryl
aryl
Prior art date
Application number
NO20081327A
Other languages
English (en)
Other versions
NO343189B1 (no
Inventor
George Hynd
Harry Finch
Michael Colin Cramp
Rosa Arienzo
Peter Crackett
Yann Griffon
Trevor Keith Harrison
John Gary Montana
Nicholas Charles Ray
Original Assignee
Argenta Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0519969.0A external-priority patent/GB0519969D0/en
Priority claimed from GB0610551A external-priority patent/GB0610551D0/en
Application filed by Argenta Discovery Ltd filed Critical Argenta Discovery Ltd
Publication of NO20081327L publication Critical patent/NO20081327L/no
Publication of NO343189B1 publication Critical patent/NO343189B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Forbindelser med formel [1] er CRTH2 antagonister, anvendelige ved behandling av lidelser som har en inflammatorisk komponent: [1] hvor: R1, R2, R3, R4 og R5 er uavhengig hydrogen, C1-C6alkyl, C1-C6fluoralkyl, cyklopropyl, halogen, -S(O)nR6, -SO2NR7R8, -NR7R8, -NR7C(O)R6, -CO2R7, -C(O)NR7R8, -C(O)R6, -NO2, -CN eller en gruppe -OR9; hvor hver R6 er uavhengig C1-C6alkyl, C1-C6fluoralkyl, cykloalkyl, aryl eller heteroaryl; R7, R8 er uavhengig C1-C6alkyl, C1-C6fluoralkyl, cykloalkyl, cykloalkyl-(C1-C6alkyl)-, aryl, heteroaryl eller hydrogen; R9 er hydrogen, C1-C6alkyl, C1-C6fluoralkyl, cykloalkyl, cylcoalkyl-(C1-C6alkyl)- eller en gruppe -SO2R6; A er -CHR10-, -C(O)-, -S(O)n-, -O- eller -NR10- hvor n er et helt tall fra 0-2 og R10 er hydrogen, C1-C3alkyl eller C1-C6fluoralkylgruppe; B er en direkte binding eller en divalent rest valgt fra -CH2-, -CH2CH2-, -CHR11-, -CR11R12-, -CH2CHR11-, -CH2CR11R12-, -CHR11CHR12- og divalente rester med formel -(CR11R12)p-Z- hvor Z er bundet til ringen som bærer R1, R2 og R3; hvor R11 er C1-C3alkyl, cyklopropyl, C1-C6fluoralkyl; R12 er metyl eller fluormetyl; p er uavhengig 1 eller 2; og Z er -O-, -NH- eller -S(O)n-, hvor n er et helt tall fra 0-2; X er en karboksylsyre, tetrazol, 3-hydroksyisoksazol, hydroksamsyre, fosfinat, fosfonat, fosfonamid eller sulfonsyregruppe eller en gruppe med formel C(=O)NHSO2R6 eller SO2NHC(=O)R6; og Y er aryl, heteroaryl, aryl-kondensert-heterocykloalkyl, heteroaryl-kondensert-cykloalkyl, heteroaryl-kondensert-heterocykloalkyl eller aryl-kondensert-cykloalkylgruppe. 1
NO20081327A 2005-09-30 2008-03-13 Kinoliner og terapeutisk anvendelse derav, samt farmasøytisk preparat NO343189B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0519969.0A GB0519969D0 (en) 2005-09-30 2005-09-30 Quinoline compounds
GB0610551A GB0610551D0 (en) 2006-05-26 2006-05-26 Quinoline compounds
PCT/GB2006/003644 WO2007036743A2 (en) 2005-09-30 2006-09-29 Quinolines and their therapeutic use

Publications (2)

Publication Number Publication Date
NO20081327L true NO20081327L (no) 2008-06-19
NO343189B1 NO343189B1 (no) 2018-11-26

Family

ID=37579213

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081327A NO343189B1 (no) 2005-09-30 2008-03-13 Kinoliner og terapeutisk anvendelse derav, samt farmasøytisk preparat

Country Status (16)

Country Link
US (1) US7858640B2 (no)
EP (1) EP1928457B1 (no)
JP (1) JP4990285B2 (no)
AU (1) AU2006296397B2 (no)
BR (1) BRPI0616452B8 (no)
CA (1) CA2622000C (no)
DK (1) DK1928457T3 (no)
EA (1) EA015358B1 (no)
ES (1) ES2399061T3 (no)
IL (1) IL190055A (no)
NO (1) NO343189B1 (no)
NZ (1) NZ566537A (no)
PL (1) PL1928457T3 (no)
PT (1) PT1928457E (no)
SI (1) SI1928457T1 (no)
WO (1) WO2007036743A2 (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008015638A (es) * 2006-06-09 2009-01-09 Icos Corp Acidos fenil aceticos sustituidos como antagonistas de dp-2.
CA2657093A1 (en) 2006-07-07 2008-01-10 Steven P. Govek Bicyclic heteroaryl inhibitors of pde4
US8138205B2 (en) 2006-07-07 2012-03-20 Kalypsys, Inc. Heteroarylalkoxy-substituted quinolone inhibitors of PDE4
EP2129661B1 (en) * 2007-03-29 2012-02-08 Pulmagen Therapeutics (Asthma) Limited Quinoline derivatives as crth2 receptor ligands
SI2139881T1 (sl) * 2007-04-04 2012-05-31 Pulmagen Therapeutics Asthma Ltd Kinolini in njihova terapevtska raba
GB0722055D0 (en) * 2007-11-09 2007-12-19 Argenta Discovery Ltd Compounds
ATE502920T1 (de) 2007-12-14 2011-04-15 Pulmagen Therapeutics Asthma Ltd Indole und ihre therapeutische verwendung
GB0818366D0 (en) * 2008-10-07 2008-11-12 Argenta Discovery Ltd Quinolin-2-one-compounds
GB0818365D0 (en) * 2008-10-07 2008-11-12 Argenta Discovery Ltd Quinoline compounds
EP2358677B1 (en) * 2008-11-17 2014-01-08 F. Hoffmann-La Roche AG Naphthylacetic acids used as crth2 antagonists or partial agonists
EP2590944B1 (en) 2010-07-05 2015-09-30 Actelion Pharmaceuticals Ltd. 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
JP2015500326A (ja) 2011-12-16 2015-01-05 アトピックス テラピューティクス リミテッド 好酸球性食道炎の治療のためのｃｒｔｈ２拮抗薬およびプロトンポンプ阻害薬の組み合わせ
EP2794563B1 (en) 2011-12-21 2017-02-22 Actelion Pharmaceuticals Ltd Heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
WO2014006585A1 (en) 2012-07-05 2014-01-09 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
AR106515A1 (es) * 2015-10-29 2018-01-24 Bayer Cropscience Ag Sililfenoxiheterociclos trisustituidos y análogos
KR20180094923A (ko) 2015-12-24 2018-08-24 교와 핫꼬 기린 가부시키가이샤 α, β 불포화 아미드 화합물
CA3025049A1 (en) 2016-05-16 2017-11-23 Pulmagen Therapeutics (Asthma) Limited Crystal of quinoline derivative
TWI804498B (zh) 2017-06-23 2023-06-11 日商協和麒麟股份有限公司 α、β不飽和醯胺化合物
WO2020172380A1 (en) 2019-02-22 2020-08-27 Gb001, Inc. Treatment of asthma patients having high baseline feno levels
WO2020227331A1 (en) * 2019-05-06 2020-11-12 Inspira, LLC Chemical entities, pharmaceutical formulations, and methods for treating fibrosis
WO2020227570A1 (en) 2019-05-08 2020-11-12 Gb001, Inc. Methods of treating chronic rhinosinusitis with pexopiprant

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58225065A (ja) 1982-06-21 1983-12-27 Nippon Shinyaku Co Ltd ２−キノロン誘導体
TW297025B (no) * 1992-02-14 1997-02-01 Squibb & Sons Inc
MXPA03007765A (es) * 2001-03-01 2003-12-08 Shionogi & Co Compuestos heteroarilo que contienen nitrogeno, que tienen actividad inhibitoria contra virus de inmunodeficiencia humana integrasa.
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
EP2045242A1 (en) * 2002-08-13 2009-04-08 Shionogi&Co., Ltd. Heterocyclic compounds having inhibitory activity against HIV integrase
KR20050055747A (ko) * 2002-10-04 2005-06-13 밀레니엄 파머슈티컬스 인코퍼레이티드 염증 질환 치료용의 ｐｇｄ2 수용체 길항제
EP1413306A1 (en) * 2002-10-21 2004-04-28 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as CRTH2 antagonists
SE0301010D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301569D0 (sv) * 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SA04250253B1 (ar) * 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
JP2008500991A (ja) * 2004-05-29 2008-01-17 ７ティーエム ファーマ エイ／エス 医学的使用のためのｃｒｔｈ２レセプターリガンド
US8524715B2 (en) * 2004-11-23 2013-09-03 Astrazeneca Ab Phenoxyacetic acid derivatives useful for treating respiratory diseases

Also Published As

Publication number Publication date
PT1928457E (pt) 2013-02-19
NO343189B1 (no) 2018-11-26
PL1928457T3 (pl) 2013-04-30
IL190055A (en) 2015-07-30
NZ566537A (en) 2010-10-29
EA015358B1 (ru) 2011-06-30
DK1928457T3 (da) 2013-02-04
BRPI0616452A2 (pt) 2011-06-21
WO2007036743A3 (en) 2007-09-20
CA2622000C (en) 2014-01-21
AU2006296397B2 (en) 2011-12-15
US20090156600A1 (en) 2009-06-18
US7858640B2 (en) 2010-12-28
EP1928457A2 (en) 2008-06-11
EA200800640A1 (ru) 2008-10-30
HK1124784A1 (en) 2009-07-24
SI1928457T1 (sl) 2013-06-28
IL190055A0 (en) 2008-08-07
JP4990285B2 (ja) 2012-08-01
AU2006296397A1 (en) 2007-04-05
EP1928457B1 (en) 2012-12-12
BRPI0616452B1 (pt) 2020-10-13
WO2007036743A2 (en) 2007-04-05
ES2399061T3 (es) 2013-03-25
BRPI0616452B8 (pt) 2021-05-25
CA2622000A1 (en) 2007-04-05
JP2009510045A (ja) 2009-03-12

Similar Documents

Publication Publication Date Title
NO20081327L (no) Kinoliner og terapeutisk anvendelse derav
PE20110835A1 (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
PE20141042A1 (es) Nuevos derivados biciclicos de dihidroquinolina-2-ona
MY148076A (en) New sulfonamide derivatives as bradykinin antagonists
NO20091596L (no) Benzoylamino-heterocykliske forbindelser som Glucokinase-(GLK)-activatorer
PE20081475A1 (es) Arilamidas sustituidas por tiazol u oxazol
EA201390717A1 (ru) 3-(аминоарил)пиридиновые соединения
PE20090334A1 (es) Compuestos de piperazina con accion herbicida
ATE448193T1 (de) ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
NO20074666L (no) Imidazo(1,2-A)pyridinforbindelser som VEGF-R2-inhibitorer
RU2010139644A (ru) Ингибитор фиброза
MY145603A (en) 2-ARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
NO20084302L (no) 2-(syklisk amino)-pyrimidonderivater som TPK1-inhibitorer
NZ586082A (en) Indole compounds and methods for treating visceral pain
NO20064015L (no) Kondenserte derivater av pyrazol
AR063240A1 (es) Derivados de n-aril pirazol,composiciones farmaceuticas que los contienen y usos para el tratamiento de la diabetes tipo2,y enfermedades relacionadas.
PE20080254A1 (es) Derivados de 1,2,3,4-tetrahidro-quinolina como inhibidores de cetp
NO20065012L (no) Tetrahydronaftyridin-derivater og fremgangsmate for fremstilling av disse
NO20076145L (no) Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav
ATE520651T1 (de) Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
WO2007115931A8 (de) Thiazolyl-dihydro-cyclopentapyrazole zur verwendung als pi3-kinase-inhibit0ren
PE20091426A1 (es) Compuestos de piridina
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
MX2011007864A (es) Isosteros para realzar la transcripcion y su uso en terapia.
GB0512944D0 (en) Indolizine compounds

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GB001, US

MM1K Lapsed by not paying the annual fees